title: Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma.
abstract: Rituximab (RTX), a monoclonal antibody against CD20, is known to cause fewer side effects than conventional anti-cancer drugs; however, infusion reaction (IR), which is specific to monoclonal antibody therapy, is frequently triggered by RTX. Therefore, we designed this study to identify risk factors based on clinical test values for developing IR after RTX administration. Eighty-nine patients with B-cell non-Hodgkin's lymphoma who had received RTX for the first time between February 2010 and March 2013, at the Gifu Municipal Hospital were enrolled as subjects. Analysis of data was conducted for 87 patients, after excluding patients whose data were missing. Univariate analysis showed significant differences in the number of patients exhibiting a soluble interleukin-2 receptor (sLL-2R) level > 2,000 U/L and hemoglobin (Hb) < lower standard limit (LSL) between the IR and non-IR groups. Multivariate analysis showed significant differences with respect to slL-2R > 2,000 U/L [odds ratio (OR), 4.463; 95% confidence interval (Cl), 1.262-15.779; P = 0.020], Hb < LSL [OR, 3.568; 95% CI, 1.071-11.890; P = 0.038], and steroid administration [OR, 0.284; 95% Cl, 0.094-0.852; P = 0.025]. Our findings show that sIL-2R > 2,000 U/L, Hb < LSL, and a lack of steroid premedication are risk factors for developing IR following RTX treatment.
authors.forename: T
authors.initials: T
authors.lastname: Tachi
authors.forename: M
authors.initials: M
authors.lastname: Yasuda
authors.forename: K
authors.initials: K
authors.lastname: Usui
authors.forename: M
authors.initials: M
authors.lastname: Umeda
authors.forename: K
authors.initials: K
authors.lastname: Nagaya
authors.forename: T
authors.initials: T
authors.lastname: Osawa
authors.forename: A
authors.initials: A
authors.lastname: Ichihashi
authors.forename: Y
authors.initials: Y
authors.lastname: Noguchi
authors.forename: H
authors.initials: H
authors.lastname: Goto
authors.forename: S
authors.initials: S
authors.lastname: Kasahara
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: C
authors.initials: C
authors.lastname: Goto
authors.forename: H
authors.initials: H
authors.lastname: Teramachi
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006454:Hemoglobins / Q000032:analysis / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects*; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D012189:Retrospective Studies; D012307:Risk Factors; D000069283:Rituximab / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D006454:Hemoglobins; D015375:Receptors, Interleukin-2; D000069283:Rituximab